Navigation Links
MiMedx Group Announces Addition of Sales Director for Europe
Date:3/9/2010

ATLANTA, March 9 /PRNewswire-FirstCall/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG.OB) announced today that Karl-Matthias Moehlmann has joined the Company to lead the establishment of key distribution partners in Europe for the sales of the Company's HydroFix™ Spine Shield product. The Company was certified in Europe for design, development, and production of post-surgical adhesion inhibiting barriers, and HydroFix™ Spine Shield is indicated for use in specific locations as a cover of the spine to provide a plane of dissection during a revision surgery.  

Last week, MiMedx Group announced that it recently received the CE Mark for HydroFix™ Spine Shield, the Company's current product offering for the European market. The device is classified as a post-surgical adhesion inhibiting barrier and is used in specific spine surgeries. The CE Mark is a mandatory conformity mark on many products placed on the market in the European Union.  The CE Mark certifies that a product conforms to the requirements of the Medical Device Directives for Europe. CE stands for Conformite Europeenne, "European Conformity" in French. The Company's product offering for the U.S. market is its HydroFix™ Vaso Shield product.  On April 20, 2009, the FDA cleared the HydroFix™ Vaso Shield, via a 510(k), as a vessel guard or cover for anterior vertebral surgery.

Parker H. "Pete" Petit, Chairman and CEO, stated, "With the addition of the CE marked HydroFix™ Spine Shield to our previously cleared HydroFix™ Vaso Shield, MiMedx is now able to market in both the U.S. and Europe.  The establishment of our relationship with Mr. Moehlmann will give us an experienced and influential partner to increase revenue through our distributors in Europe, as well as, represent MiMedx at major Euro Spine Society Meetings. He brings to the Company a wealth of experience and relationships. Mr. Moehlmann has an extensive orthopedic background with a number of leading international organizations, including Synthes Spine, Medtronic Kyphon and Depuy Spine, and he is based in Hannover, Germany. We are pleased to have Matthias as a part of the MiMedx organization."

HydroFix™ Spine Shield is only available in Europe and is not available in the United States. Conversely, HydroFix™ Vaso Shield is only available in the U.S. and is not available in Europe.

About MiMedx Group, Inc.

MiMedx Group, Inc. is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and is in the process of transitioning from a development-focused concern to an operating company focused on sales growth and profitability. The Company's assets include intellectual property protecting its CollaFix™ collagen-based technology for augmentation of soft and connective tissue diseases and trauma and intellectual property protecting a novel durable hydrogel technology. The Company has received FDA clearance for its first durable hydrogel product, the HydroFix™ Vaso Shield indicated for use as a cover for vessels following anterior spinal surgery. More information about MiMedx Group can be found at www.mimedx.com.

Important Note regarding forward-looking statements and risk factors.  This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include those regarding the effectiveness of the HydroFix™ Spine Shield in reducing the risks associated with revision surgeries, and the impact of the Company's sales director for Europe in leading the establishment of distributor partners in Europe and increasing the Company's revenues. These risks and uncertainties including, the ability of  HydroFix™ Spine Shield to perform as designed,  that the Company currently requires additional capital to survive and achieve its goals, which may be difficult or impossible to obtain, that the Company fails to establish key distributor partners in Europe and increase its revenues, that the Company may not develop additional products or receive requisite regulatory clearances and/or approvals to be able to market such  products or that such clearances or approvals may be delayed, that the Company may not be able to establish an effective distribution system for its products, and that the Company's products may not gain acceptance in the marketplace or that acceptance may be delayed.  The risks and uncertainties also include the risk factors detailed in its Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended March 31, 2009, and its most recent Form 10-Q filed on November 16, 2009.  The Company does not undertake to update its forward-looking statements.

SOURCE MiMedx Group, Inc.

Back to top

RELATED LINKS
http://www.mimedx.com

'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device
2. MiMedx Group Announces CE Mark for the HydroFix(TM) Spine Shield
3. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
4. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
7. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
8. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
9. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
10. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
11. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017  Genesis Healthcare Services has merged ... was made by Bill Monast , President and ... and Nathan Feltman , executives with Home Health ... LLC. This acquisition helps Hospice Cloud ... technology enabled durable medical equipment (DME) solutions for the ...
(Date:2/23/2017)... 23, 2017 ITL Limited, ( ASX: ITD ), an ... the half year ended 31 December 2016 compared with the previous ... can be viewed here . Highlights ... up 104%) Earnings per share of 2.2 cents ... $17.5m (Dec 2015: $15.7m; up 11%) Profit before ...
(Date:2/23/2017)... GUIYANG, China , 23. Februar 2017 ... Area , eine nationale Wirtschaftszone in der südwestlichen chinesischen Provinz ... Beschleunigung der Errichtung einer Innovationsplattform aktiv an der Entwicklung einer ... Continue Reading ... ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ ... Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he ... and his attempts to overcome them. , Schanssema, initially unsure of the career path ...
(Date:2/24/2017)... ... 2017 , ... The International Association of Eating Disorders Professionals (iaedp) announces the ... body image mannequin art competition. Selected from 15 submissions from around the nation, the ... the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head Over ... on February 12th. Ms. Esparza qualified into this prestigious status after winning ... in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in the ...
(Date:2/23/2017)... ... 23, 2017 , ... The 89th Academy Awards will be celebrated this weekend, ... Policy Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” ... is the Center for American Progress (CAP), for its report, Lessons From State Performance ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss ... WE TV’s “Mama June: From Not to Hot,” which will begin airing on February ... Shannon, known to millions from the 2012 reality television series, “Here Comes Honey Boo ...
Breaking Medicine News(10 mins):